<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="797">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096496</url>
  </required_header>
  <id_info>
    <org_study_id>QoL-APL0816</org_study_id>
    <nct_id>NCT03096496</nct_id>
  </id_info>
  <brief_title>Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy</brief_title>
  <official_title>Long-term Quality of Life Symptom Burden in Acute Promyelocytic Leukemia (APL) Patients Treated With Arsenic Trioxide (ATO) or Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective and international observational study run by the GIMEMA. All data will
      be centrally collected and analyzed at the GIMEMA Data Center in Rome (Italy). Patients
      reported outcomes will be collected using internationally validated questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cross-sectional differences in fatigue severity</measure>
    <time_frame>Two years after study entry.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>GIMEMA APL0406 patients</arm_group_label>
    <description>APL survivors previously enrolled in GIMEMA APL0406 clinical trial and in 1st molecular CR after third consolidation treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QoL questionnaires</intervention_name>
    <arm_group_label>GIMEMA APL0406 patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients previously enrolled in a phase III randomized controlled trial that compared the
        efficacy and toxicity of standard ATRA plus chemotherapy versus ATRA plus ATO in
        low-intermediate risk APL patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  APL survivors enrolled in GIMEMA APL0406 clinical trial and in first molecular CR
             after third consolidation treatment

          -  Written informed consent.

        Exclusion Criteria:

          -  APL patients previously enrolled in GIMEMA APL0406 trial who cannot be reached or who
             are lost to follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Efficace</last_name>
    <role>Study Chair</role>
    <affiliation>GIMEMA Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesca Tartaglia</last_name>
    <email>f.tartaglia@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabio Efficace</last_name>
    <email>f.efficace@gimema.it</email>
  </overall_contact_backup>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>January 24, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <keyword>acute promyelocytic leukemia</keyword>
  <keyword>ATO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
